

Gary H Lyman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789224/publications.pdf>

Version: 2024-02-01

544
papers

57,454
citations

1294

109
h-index

1185

228
g-index

553
all docs

553
docs citations

553
times ranked

41164
citing authors

#	ARTICLE	IF	CITATIONS
1	Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane Library, 2022, 2022, CD003039.	1.5	85
2	Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Investigation, 2022, 40, 115-123.	0.6	20
3	Examining pain among non-Hispanic Black and non-Hispanic White patients with cancer visiting emergency departments: CONCERN (Comprehensive Oncologic Emergencies Research Network). Academic Emergency Medicine, 2022, 29, 364-368.	0.8	0
4	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. Cancer Investigation, 2022, 40, 17-25.	0.6	2
5	Use of Biosimilar Medications in Oncology. JCO Oncology Practice, 2022, 18, 177-186.	1.4	15
6	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193.	2.6	12
7	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. BMC Health Services Research, 2022, 22, 432.	0.9	1
8	Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. Advances in Therapy, 2022, 39, 2778-2795.	1.3	3
9	Palliative Care Needs and Clinical Outcomes of Patients with Advanced Cancer in the Emergency Department. Journal of Palliative Medicine, 2022, 25, 1115-1121.	0.6	2
10	Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies. JCO Oncology Practice, 2021, 17, e406-e415.	1.4	8
11	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 685-693.	0.8	66
12	Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leukemia and Lymphoma, 2021, 62, 1203-1210.	0.6	9
13	Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Supportive Care in Cancer, 2021, 29, 2179-2186.	1.0	22
14	Expenditures among young adults with acute lymphoblastic leukemia by site of care. Cancer, 2021, 127, 1901-1911.	2.0	4
15	Cancer pain management in the emergency department: a multicenter prospective observational trial of the Comprehensive Oncologic Emergencies Research Network (CONCERN). Supportive Care in Cancer, 2021, 29, 4543-4553.	1.0	19
16	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	2.5	431
17	Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer. Cancer Investigation, 2021, 39, 205-213.	0.6	17
18	Aligning Cancer Clinical Trials With Cancer Burden. JAMA Oncology, 2021, 7, 357.	3.4	5

#	ARTICLE	IF	CITATIONS
19	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.	0.6	4
20	Medications in Single-Dose Vials and Implications of Discarded Injectable Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1507.	3.8	4
21	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 2037-2048.	0.8	51
22	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
23	Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1145-1159.	1.1	5
24	Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era. <i>Frontiers in Oncology</i> , 2021, 11, 697908.	1.3	13
25	Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma. <i>Cancer Investigation</i> , 2021, 39, 449-456.	0.6	2
26	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
27	Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. <i>Frontiers in Immunology</i> , 2021, 12, 706186.	2.2	27
28	Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. <i>JCO Oncology Practice</i> , 2021, 17, e1235-e1245.	1.4	13
29	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	3.4	42
30	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021, 5, 4721-4726.	2.5	10
31	Healthcare costs of patients with cancer stratified by Khorana score risk levels. <i>Journal of Medical Economics</i> , 2021, 24, 866-873.	1.0	1
32	Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. <i>Cancer</i> , 2021, 127, 1459-1468.	2.0	98
33	Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. <i>Cancer Investigation</i> , 2021, 39, 1-5.	0.6	7
34	Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 18-21.	2.3	32
35	Expenditures in Young Adults with Hodgkin Lymphoma: NCI-designated Comprehensive Cancer Centers vs. Other Sites. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0321.2021.	1.1	0
36	Observation Unit Use Among Patients with Cancer Following Emergency Department Visits: Results of a Multicenter Prospective Cohort from CONCERN. <i>Academic Emergency Medicine</i> , 2021, , .	0.8	4

#	ARTICLE	IF	CITATIONS
37	Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 925-932.	1.0	38
38	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	0.8	971
39	Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. <i>Current Medical Research and Opinion</i> , 2020, 36, 483-495.	0.9	14
40	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
41	The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 121-126.	0.8	16
42	Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1969.	3.4	8
43	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	0.8	201
44	Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1309-1315.	0.5	2
45	Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2020, 191, S79-S84.	0.8	22
46	Crowdsourcing in Crisis: Rising to the Occasion. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 551-554.	1.0	8
47	Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. <i>Targeted Oncology</i> , 2020, 15, 467-475.	1.7	11
48	Randomized Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative. <i>Cancer Investigation</i> , 2020, 38, 537-542.	0.6	7
49	COVID-19, Cancer, and Consequences: Where Are We Now?. <i>Cancer Investigation</i> , 2020, 38, 431-435.	0.6	6
50	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. <i>Cancer Medicine</i> , 2020, 9, 8062-8073.	1.3	23
51	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	2.2	21
52	Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. <i>Blood Advances</i> , 2020, 4, 4045-4051.	2.5	13
53	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. <i>BMC Medical Research Methodology</i> , 2020, 20, 113.	1.4	37
54	Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103005.	2.0	7

#	ARTICLE	IF	CITATIONS
55	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
56	Financial Toxicity, Financial Abuse, or Financial Torture: Let's Call It What It Is!. <i>Cancer Investigation</i> , 2020, 38, 139-142.	0.6	6
57	Crowdsourcing a crisis response for COVID-19 in oncology. <i>Nature Cancer</i> , 2020, 1, 473-476.	5.7	66
58	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	1.9	60
59	Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. <i>Cancer</i> , 2020, 126, 1736-1748.	2.0	23
60	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
61	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 12-22.	2.3	70
62	Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: a retrospective observational study. <i>BMC Cancer</i> , 2019, 19, 792.	1.1	14
63	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2141-2151.	1.9	41
64	Validation of the Emergency Severity Index (Version 4) for the Triage of Adult Emergency Department Patients With Active Cancer. <i>Journal of Emergency Medicine</i> , 2019, 57, 354-361.	0.3	22
65	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2916-2946.	0.8	127
66	Rumors of the Death of Biosimilars Have Been Greatly Exaggerated. <i>Cancer Investigation</i> , 2019, 37, 325-326.	0.6	2
67	Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. <i>Thrombosis Research</i> , 2019, 180, 37-42.	0.8	15
68	Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. <i>BMC Medical Research Methodology</i> , 2019, 19, 119.	1.4	26
69	Febrile Neutropenia: An Ounce of Prevention or a Pound of Cure. <i>Journal of Oncology Practice</i> , 2019, 15, 27-29.	2.5	5
70	Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments. <i>JAMA Network Open</i> , 2019, 2, e190979.	2.8	99
71	Biosimilars: what the oncologist should know. <i>Future Oncology</i> , 2019, 15, 1147-1165.	1.1	24
72	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	13.9	520

#	ARTICLE	IF	CITATIONS
73	Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	7
74	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 173, 158-163.	0.8	228
75	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 840-847.	2.3	101
76	Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 380-386.	1.1	51
77	Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. <i>Clinical Lung Cancer</i> , 2018, 19, e163-e169.	1.1	24
78	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018, 23, 247-255.	1.9	63
79	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. <i>Blood Reviews</i> , 2018, 32, 81-87.	2.8	41
80	A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. <i>Supportive Care in Cancer</i> , 2018, 26, 7-20.	1.0	51
81	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Annals of Surgical Oncology</i> , 2018, 25, 356-377.	0.7	130
82	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 495-499.	2.5	37
83	Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. <i>Journal of Oncology Practice</i> , 2018, 14, e176-e185.	2.5	74
84	Reply to S.D. Lucio. <i>Journal of Clinical Oncology</i> , 2018, 36, 2127-2127.	0.8	0
85	Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report. <i>Journal of Oncology Practice</i> , 2018, 14, e801-e814.	2.5	3
86	American Society of Clinical Oncology Statement: Biosimilars in Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1260-1265.	0.8	88
87	Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety. <i>Journal of Clinical Oncology</i> , 2018, 36, 1773-1776.	0.8	4
88	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 242-245.	2.5	10
89	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 399-413.	0.8	190
90	Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). <i>Journal of Clinical Oncology</i> , 2018, 36, 2017-2023.	0.8	967

#	ARTICLE	IF	CITATIONS
91	Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. <i>Journal of Oncology Practice</i> , 2018, 14, e194-e200.	2.5	29
92	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	0.8	131
93	American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	8
94	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 2647-2655.	0.8	262
95	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 491-497.	2.3	11
96	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018, 378, 2036-2044.	13.9	56
97	Integrative omics to detect bacteremia in patients with febrile neutropenia. <i>PLoS ONE</i> , 2018, 13, e0197049.	1.1	10
98	Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. <i>Thrombosis Research</i> , 2018, 164, S112-S118.	0.8	114
99	Immune-related Adverse Events in Cancer Patients. <i>Academic Emergency Medicine</i> , 2018, 25, 819-827.	0.8	18
100	Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. <i>BMC Cancer</i> , 2018, 18, 44.	1.1	230
101	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018, 379, 694-695.	13.9	15
102	Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 699-708.e1.	0.6	24
103	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	0.6	12
104	The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category. <i>Blood</i> , 2018, 132, 3798-3798.	0.6	1
105	Comparative analysis of multigene assays (MGA) effects on chemotherapy (CT) de-escalation for women with NO, ER+ early stage breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e12519-e12519.	0.8	3
106	Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2018, 132, 3531-3531.	0.6	0
107	Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 33-42.	0.5	3
108	Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 39-52.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 196-198.	2.5	63
110	Chemotherapy Use at the End of Life in Uganda. <i>Journal of Global Oncology</i> , 2017, 3, 711-719.	0.5	6
111	Depression and Health Care Utilization at End-of-Life Among Older Adults with Non-Small Cell Lung Cancer (TH320D). <i>Journal of Pain and Symptom Management</i> , 2017, 53, 326-327.	0.6	0
112	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	0.8	109
113	Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment. <i>Cancer</i> , 2017, 123, 2506-2515.	2.0	7
114	Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China. <i>Cancer Investigation</i> , 2017, 35, 345-357.	0.6	5
115	Vascular Complications of Cancer and Cancer Therapy. , 2017, , 215-240.		0
116	The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. <i>Supportive Care in Cancer</i> , 2017, 25, 2619-2629.	1.0	45
117	Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. <i>Pharmacoeconomics</i> , 2017, 35, 425-438.	1.7	25
118	Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. <i>JAMA Oncology</i> , 2017, 3, 996.	3.4	134
119	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 561-564.	0.8	359
120	A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1543-1550.	2.3	19
121	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 461-470.	0.6	13
122	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. <i>JAMA Oncology</i> , 2017, 3, 374.	3.4	58
123	Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. <i>Supportive Care in Cancer</i> , 2017, 25, 439-447.	1.0	38
124	Predicting neutropenia risk in patients with cancer using electronic data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e-e.	2.2	16
125	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	1.8	53
126	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1520-1541.	2.3	104

#	ARTICLE	IF	CITATIONS
127	Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	3
128	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017, 1, pkx009.	1.4	6
129	American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 207-210.	2.5	32
130	Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2017, 35, 1845-1854.	0.8	87
131	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	0.8	454
132	Reply to L. Del Mastro and A. Prat. <i>Journal of Clinical Oncology</i> , 2017, 35, 1139-1139.	0.8	0
133	Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 7s-9s.	2.5	7
134	The role of chronic disease in the costs of potentially preventable emergency department use during treatment: A regional study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6505-6505.	0.8	1
135	Patterns in provider types and cost of surveillance testing in early-stage breast cancer patients: A regional study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6582-6582.	0.8	1
136	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18290-e18290.	0.8	1
137	Neutropenia. , 2017, , 3085-3088.		0
138	Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo).. <i>Journal of Clinical Oncology</i> , 2017, 35, 280-280.	0.8	0
139	Out of system (OOS) costs for oncology clinics treating patients with breast, colorectal, and non-small cell lung cancer in Washington state.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5-5.	0.8	0
140	Systematic reviews and meta-analyses in geriatric oncology.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21517-e21517.	0.8	0
141	Predictors of advanced imaging use during breast cancer surveillance.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18337-e18337.	0.8	0
142	Abstract 2767: Consistency of standing orders for primary prophylactic CSF within a national network of community oncology practices: SWOG intergroup trial S1415CD. , 2017, , .		0
143	Issues on the Use of White Blood Cell Growth Factors in Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e528-e532.	1.8	3
144	Innovations in American Society of Clinical Oncology Practice Guideline Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 3213-3220.	0.8	14

#	ARTICLE	IF	CITATIONS
145	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	0.8	18
146	Evaluation and Regulation of Oncology Drug Approval. <i>JAMA Oncology</i> , 2016, 2, 728.	3.4	4
147	Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2066.	0.8	17
148	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) â€”Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427.	0.8	112
149	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 43-73.	157.7	497
150	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 203-239.	157.7	419
151	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3872-3879.	0.8	28
152	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	0.8	538
153	Biomarker Tests for Molecularly Targeted Therapies â€” The Key to Unlocking Precision Medicine. <i>New England Journal of Medicine</i> , 2016, 375, 4-6.	13.9	101
154	A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867.	1.9	54
155	Reply to M.G. McNamara et al and T.H. Oo. <i>Journal of Clinical Oncology</i> , 2016, 34, 517-518.	0.8	0
156	Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 483-492.	1.0	13
157	Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology. <i>Genetics in Medicine</i> , 2016, 18, 780-787.	1.1	17
158	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-635.	0.8	651
159	Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs. <i>JAMA Oncology</i> , 2016, 2, 425.	3.4	19
160	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016, 34, 381-386.	0.8	173
161	Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 283-290.	0.6	12
162	Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016, 128, 1422-1422.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Incidence of bone metastases in U.S. patients with solid tumors.. Journal of Clinical Oncology, 2016, 34, e13099-e13099.	0.8	3
164	The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care.. Journal of Clinical Oncology, 2016, 34, 78-78.	0.8	1
165	Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.. Journal of Clinical Oncology, 2016, 34, 32-32.	0.8	4
166	Value in cancer care: Regional initiative to improve care through data reporting and interventions.. Journal of Clinical Oncology, 2016, 34, 34-34.	0.8	0
167	Measuring adherence to a Choosing Wisely recommendation in a regional oncology clinic.. Journal of Clinical Oncology, 2016, 34, 196-196.	0.8	0
168	Regional initiative to use data transparency to improve cancer care.. Journal of Clinical Oncology, 2016, 34, 39-39.	0.8	0
169	HICOR IQ: Developing a regional oncology metric reporting platform.. Journal of Clinical Oncology, 2016, 34, 165-165.	0.8	0
170	Regional engagement to define, report, and use quality metrics to improve palliative care in oncology.. Journal of Clinical Oncology, 2016, 34, 282-282.	0.8	4
171	Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy.. Journal of Clinical Oncology, 2016, 34, 9078-9078.	0.8	1
172	Burden of febrile neutropenia hospitalizations (FNH) in U.S. clinical practice, by use and patterns of colony-stimulating factor prophylaxis (CP).. Journal of Clinical Oncology, 2016, 34, 6568-6568.	0.8	0
173	End of life services for cancer patients: A population-based evaluation.. Journal of Clinical Oncology, 2016, 34, 6524-6524.	0.8	0
174	Health care utilization and costs at end of life among patients with leukemia or lymphoma in a regional cancer registry-insurance claims linked database.. Journal of Clinical Oncology, 2016, 34, 184-184.	0.8	0
175	Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology, 2015, 1, 158.	3.4	55
176	Assessing patients'™ risk of febrile neutropenia: is there a correlation between physician'™ assessed risk and model'™ predicted risk?. Cancer Medicine, 2015, 4, 1153-1160.	1.3	27
177	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood, 2015, 126, 2790-2797.	0.6	46
178	Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1383-1393.	2.3	89
179	Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 979-986.	2.3	17
180	Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, e1-e7.	2.3	39

#	ARTICLE	IF	CITATIONS
181	Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. <i>Journal of Oncology Practice</i> , 2015, 11, 338-343.	2.5	27
182	The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. <i>SpringerPlus</i> , 2015, 4, 396.	1.2	16
183	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656.	0.8	911
184	Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. <i>Journal of Oncology Practice</i> , 2015, 11, 47-54.	2.5	61
185	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	0.8	783
186	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3199-3212.	0.8	680
187	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
188	When to Offer Thromboprophylaxis to Patients With Advanced Pancreatic Cancer: Shedding Light on the Path Forward. <i>Journal of Clinical Oncology</i> , 2015, 33, 1995-1997.	0.8	7
189	Appropriate Role for Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 232-234.	0.8	23
190	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Oncology Practice</i> , 2015, 11, e442-e444.	2.5	115
191	When is good, good enough? Methodological pragmatism for sustainable guideline development. <i>Implementation Science</i> , 2015, 10, 28.	2.5	15
192	Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 659-667.	1.1	13
193	Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. <i>JAMA Oncology</i> , 2015, 1, 1098.	3.4	49
194	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. <i>Genetics in Medicine</i> , 2015, 17, 63-67.	1.1	16
195	Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. <i>Blood</i> , 2015, 126, 427-427.	0.6	12
196	Evolving Healthcare Quality in Top Tertiary General Hospitals in China during the China Healthcare Reform (2010-2012) from the Perspective of Inpatient Mortality. <i>PLoS ONE</i> , 2015, 10, e0140568.	1.1	14
197	Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN. , 2015, , .		0
198	CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2079-TPS2079.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. <i>American Health and Drug Benefits</i> , 2015, 8, 273-82.	0.5	29
200	Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. <i>Journal of Medical Economics</i> , 2014, 17, 32-42.	1.0	26
201	Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. <i>Cancer Medicine</i> , 2014, 3, 434-444.	1.3	85
202	Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. <i>Supportive Care in Cancer</i> , 2014, 22, 3275-3285.	1.0	21
203	Imagine a world without cancer. <i>BMC Cancer</i> , 2014, 14, 186.	1.1	12
204	Reply to L.K. Griffeth et al and J.E. Battley et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 2812-2813.	0.8	0
205	Reply to I.A. Voutsadakis et al and A. Goyal et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3902-3904.	0.8	6
206	Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 446-453.	0.6	9
207	Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 190-199.	2.0	230
208	Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 1502-1506.	0.8	167
209	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2014, 32, 1365-1383.	0.8	713
210	Biosimilars: A cure to the U.S. health care cost conundrum?. <i>Blood Reviews</i> , 2014, 28, 263-268.	2.8	22
211	Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need. <i>Internal and Emergency Medicine</i> , 2014, 9, 497-499.	1.0	9
212	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. <i>Journal of Clinical Oncology</i> , 2014, 32, 1840-1850.	0.8	486
213	Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. <i>Thrombosis Research</i> , 2014, 133, S122-S127.	0.8	44
214	Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 190-198.	0.5	69
215	Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure. <i>Annals of Internal Medicine</i> , 2014, 160, 672.	2.0	100
216	Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia. <i>Blood</i> , 2014, 124, 2601-2601.	0.6	4

#	ARTICLE	IF	CITATIONS
217	Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study.. Journal of Clinical Oncology, 2014, 32, 558-558.	0.8	3
218	Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study.. Journal of Clinical Oncology, 2014, 32, 532-532.	0.8	0
219	A national survey of breast cancer screening in rural America.. Journal of Clinical Oncology, 2014, 32, 6546-6546.	0.8	0
220	Regional initiative to define, collect, and report value metrics in cancer care.. Journal of Clinical Oncology, 2014, 32, 25-25.	0.8	0
221	Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen. Cancer, 2013, 119, 3703-3709.	2.0	9
222	Chemotherapy dosing in overweight and obese patients with cancer. Nature Reviews Clinical Oncology, 2013, 10, 451-459.	12.5	79
223	Update on the Role of Etoposides in Metastatic Breast Cancer. Current Breast Cancer Reports, 2013, 5, 51-56.	0.5	2
224	A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Research and Treatment, 2013, 139, 863-872.	1.1	39
225	Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer. Critical Reviews in Oncology/Hematology, 2013, 88, 1-18.	2.0	49
226	Multidisciplinary Care of Patients with Early-Stage Breast Cancer. Surgical Oncology Clinics of North America, 2013, 22, 299-317.	0.6	4
227	Counting the costs of cancer care. Lancet Oncology, The, 2013, 14, 1142-1143.	5.1	11
228	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 2189-2204.	0.8	717
229	Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies. Journal of Geriatric Oncology, 2013, 4, 310-318.	0.5	20
230	Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecologic Oncology, 2013, 129, 74-80.	0.6	75
231	Appropriate chemotherapy dosing in obese patients with cancer. Nature Reviews Clinical Oncology, 2013, 10, 664-664.	12.5	5
232	Comparative Effectiveness Research in Oncology. Oncologist, 2013, 18, 752-759.	1.9	18
233	Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects. Journal of the National Cancer Institute, 2013, 105, 929-936.	3.0	30
234	Reply to T.H. Oo. Journal of Clinical Oncology, 2013, 31, 4381-4382.	0.8	3

#	ARTICLE	IF	CITATIONS
235	The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Oncology</i> , 2013, 24, 2475-2484.	0.6	161
236	Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. <i>Genetics in Medicine</i> , 2013, 15, 203-211.	1.1	44
237	Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis. <i>Oncologist</i> , 2013, 18, 1321-1329.	1.9	161
238	American Society of Clinical Oncology 2013 Top Five List in Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 4362-4370.	0.8	126
239	Will Biosimilars Gain Momentum?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1291-1297.	2.3	18
240	Myeloid Growth Factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1266-1290.	2.3	53
241	Risk Score For Venous Thromboembolism (VTE) In Ambulatory Patients: Impact Of Cancer Type and Risk Score On VTE Incidence, Early Mortality and Progression-Free Survival. <i>Blood</i> , 2013, 122, 3597-3597.	0.6	2
242	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e337-e345.	1.8	16
243	National survey of breast cancer screening in rural America.. <i>Journal of Clinical Oncology</i> , 2013, 31, 13-13.	0.8	3
244	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e337-e345.	1.8	9
245	Reply to P.K.L. Chin et al, P. Chambers et al, and J.H. Beumer et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3898-3899.	0.8	0
246	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 2912-2918.	0.8	301
247	Making Genuine Progress Against Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3448-3451.	0.8	13
248	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012, 8, e65-e66.	2.5	4
249	Comparative Effectiveness Research in Oncology: An Overview. <i>Journal of Clinical Oncology</i> , 2012, 30, 4181-4184.	0.8	50
250	Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?. <i>Journal of Clinical Oncology</i> , 2012, 30, 580-581.	0.8	15
251	Weight-Based Chemotherapy Dosing in Obese Patients With Cancer: Back to the Future. <i>Journal of Oncology Practice</i> , 2012, 8, e62-e64.	2.5	20
252	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012, 8, e59-e61.	2.5	33

#	ARTICLE	IF	CITATIONS
253	American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review—Based Consensus Methodology. <i>Journal of Clinical Oncology</i> , 2012, 30, 3136-3140.	0.8	146
254	Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer. <i>Chemotherapy</i> , 2012, 58, 8-18.	0.8	40
255	Epilogue: The Peril and the Promise of Comparative Effectiveness Research in Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 4282-4282.	0.8	3
256	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , 2012, 142, 265-266.	0.4	3
257	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 1553-1561.	0.8	430
258	Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer. <i>Pharmacoeconomics</i> , 2012, 30, 103-118.	1.7	9
259	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Annals of Surgical Oncology</i> , 2012, 19, 3313-3324.	0.7	101
260	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. <i>Genetics in Medicine</i> , 2012, 14, 633-642.	1.1	36
261	A Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients with T3, Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs. <i>Value in Health</i> , 2012, 15, 1014-1021.	0.1	21
262	Costs Associated with Febrile Neutropenia in the US. <i>Pharmacoeconomics</i> , 2012, 30, 809-823.	1.7	61
263	Pharmacoeconomics of the Myeloid Growth Factors. <i>Pharmacoeconomics</i> , 2012, 30, 497-511.	1.7	24
264	Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 532-540.	1.8	24
265	Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. <i>Cancer</i> , 2012, 118, 3377-3386.	2.0	933
266	Cost effectiveness of gene expression profiling for early stage breast cancer. <i>Cancer</i> , 2012, 118, 6298-6299.	2.0	4
267	Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 301-310.	1.1	54
268	Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 296-308.	2.0	21
269	Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 625-630.	0.6	28
270	Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors. , 2012, , 409-420.		1

#	ARTICLE	IF	CITATIONS
271	Current patterns of chemotherapy and supportive care for early-stage breast cancer (ESBC).. Journal of Clinical Oncology, 2012, 30, 1062-1062.	0.8	0
272	Prospective cohort study of chemotherapy-associated toxicity and supportive care in oncology practice.. Journal of Clinical Oncology, 2012, 30, 9135-9135.	0.8	0
273	The incidence of venous thromboembolism in cancer patients: a real-world analysis. Clinical Advances in Hematology and Oncology, 2012, 10, 40-2.	0.3	11
274	Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies. Journal of Clinical Oncology, 2011, 29, 1757-1764.	0.8	197
275	Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy. Medical Care, 2011, 49, 649-657.	1.1	16
276	A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Current Opinion in Hematology, 2011, 18, 1-10.	1.2	6
277	Comparison of Demographic Characteristics, Surgical Resection Patterns, and Survival Outcomes for Veterans and Nonveterans with Non-small Cell Lung Cancer in the Pacific Northwest. Journal of Thoracic Oncology, 2011, 6, 1726-1732.	0.5	22
278	NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-22.	2.3	118
279	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 914-932.	2.3	25
280	Biosimilars: Are They Ready for Primetime in the United States?. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 934-943.	2.3	29
281	Systematic Review of 99mTc Human Serum Albumin and 99mTc Sulfur Colloid Studies of Sentinel Lymph Node Biopsy of Cutaneous Melanoma of the Head and Neck. Laryngoscope, 2011, 121, S106-S106.	1.1	0
282	Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Research and Treatment, 2011, 127, 511-520.	1.1	9
283	Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Research and Treatment, 2011, 130, 255-266.	1.1	15
284	Breast Cancer Screening with Mammography. Current Oncology Reports, 2011, 13, 63-70.	1.8	18
285	Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer, 2011, 117, 1917-1927.	2.0	195
286	Venous thromboembolism in the patient with cancer. Cancer, 2011, 117, 1334-1349.	2.0	158
287	Reply to risk of mortality in patients with cancer who experience febrile neutropenia. Cancer, 2011, 117, 5246-5246.	2.0	0
288	Personalized Medicine and Cancer Supportive Care: Appropriate Use of Colony-Stimulating Factor Support of Chemotherapy. Journal of the National Cancer Institute, 2011, 103, 910-913.	3.0	29

#	ARTICLE	IF	CITATIONS
289	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Oncology Practice</i> , 2011, 7, 395-398.	2.5	52
290	Sentinel Node Biopsy for Head and Neck Melanoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 375-382.	1.1	120
291	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 1479-1487.	0.8	186
292	Reply to S. Hapani et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3490-3491.	0.8	1
293	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2011, 29, 4189-4198.	0.8	822
294	Commentary: Chemotherapy Dosing in Obese Patients With Cancer—The Need for Evidence-Based Clinical Practice Guidelines. <i>Journal of Oncology Practice</i> , 2011, 7, 17-18.	2.5	10
295	Commentary: Should Cost and Comparative Value of Treatments Be Considered in Clinical Practice Guidelines?. <i>Journal of Oncology Practice</i> , 2011, 7, 398-401.	2.5	6
296	Long-Term Outcomes of Myeloid Growth Factor Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 945-952.	2.3	13
297	Neutropenia. , 2011, , 2506-2509.		0
298	Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 2670-2670.	0.6	3
299	Comparative effectiveness research and genomic personalized medicine. <i>Personalized Medicine</i> , 2010, 7, 223-227.	0.8	5
300	Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2010, 28, 2914-2924.	0.8	167
301	Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 771-776.	1.1	2
302	Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. <i>Journal of Hematology and Oncology</i> , 2010, 3, 27.	6.9	12
303	Risk of mortality in patients with cancer who experience febrile neutropenia. <i>Cancer</i> , 2010, 116, 5555-5563.	2.0	202
304	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 203-210.	2.0	27
305	Economic Implications of 21-Gene Recurrence Score Assay: US Multicenter Experience. <i>Journal of Clinical Oncology</i> , 2010, 28, e382-e382.	0.8	8
306	Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy. <i>Cancer Treatment and Research</i> , 2010, 157, 145-165.	0.2	16

#	ARTICLE	IF	CITATIONS
307	Reply to N. Lathia et al. Journal of Clinical Oncology, 2010, 28, e764-e764.	0.8	0
308	Breast Cancer Screening: Science, Society and Common Sense. Cancer Investigation, 2010, 28, 1-6.	0.6	5
309	How We Treat Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. Journal of Oncology Practice, 2010, 6, 149-152.	2.5	34
310	A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer. Cancer Investigation, 2010, 28, 978-982.	0.6	65
311	Availability of Experimental Therapy Outside Oncology Randomized Clinical Trials in the United States. Journal of Clinical Oncology, 2010, 28, 5067-5073.	0.8	16
312	Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thrombosis Research, 2010, 126, 113-118.	0.8	115
313	Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines. Thrombosis Research, 2010, 125, S120-S127.	0.8	38
314	Anthracyclines in the Treatment of Early-Stage Breast Cancer: Ally or Adversary?. Cancer Investigation, 2010, 28, 217-219.	0.6	2
315	Introduction to the Hematopoietic Growth Factors. Cancer Treatment and Research, 2010, 157, 3-10.	0.2	2
316	Granulocyte Colony-Stimulating Factors and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome. Cancer Treatment and Research, 2010, 157, 167-178.	0.2	2
317	The Myeloid Growth Factors. Cancer Treatment and Research, 2010, 157, 109-125.	0.2	1
318	The Economics of the Hematopoietic Growth Factors. Cancer Treatment and Research, 2010, 157, 403-418.	0.2	0
319	Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early-Stage Breast Cancer. Cancer Investigation, 2009, 27, 885-890.	0.6	6
320	Preventing Venous Thromboembolism in Cancer Patients: Can We Do Better?. Journal of Oncology Practice, 2009, 5, 165-166.	2.5	1
321	Comparative Effectiveness Research in Oncology: The Need for Clarity, Transparency and Vision. Cancer Investigation, 2009, 27, 593-597.	0.6	14
322	Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. Cancer Investigation, 2009, 27, 953-959.	0.6	19
323	Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology, 2009, 27, 4821-4826.	0.8	149
324	Does Treatment Intensity Matter in Superficial Bladder Cancer? Consensus, Clinical Practice, and Confounding. Journal of the National Cancer Institute, 2009, 101, 543-545.	3.0	3

#	ARTICLE	IF	CITATIONS
325	Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. <i>Clinical Therapeutics</i> , 2009, 31, 1092-1104.	1.1	62
326	Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?. <i>Cancer</i> , 2009, 115, 2660-2670.	2.0	73
327	Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. <i>Cancer</i> , 2009, 115, 5319-5328.	2.0	39
328	Thromboprophylaxis with low molecular weight heparin in medical patients with cancer. <i>Cancer</i> , 2009, 115, 5637-5650.	2.0	31
329	Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy. <i>Value in Health</i> , 2009, 12, 217-225.	0.1	46
330	Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. <i>Current Medical Research and Opinion</i> , 2009, 25, 401-411.	0.9	58
331	Cancer and Thrombosis: Back to the Future<i>Renewed Interest in an Old Problem</i>. <i>Cancer Investigation</i> , 2009, 27, 472-473.	0.6	8
332	Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. <i>Journal of Clinical Oncology</i> , 2009, 27, 4919-4926.	0.8	162
333	Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 99-108.	2.3	265
334	Breast Cancer Screening and Diagnosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 1060-1096.	2.3	317
335	Myeloid Growth Factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 64-83.	2.3	96
336	Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2009, 114, 490-490.	0.6	12
337	Impact of Decision-Support On Clinicians' Assessment of Febrile Neutropenia Risk.. <i>Blood</i> , 2009, 114, 1409-1409.	0.6	0
338	Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. <i>Cancer</i> , 2008, 113, 224-224.	2.0	1
339	Subsequent Malignancies in Children Treated for Hodgkin's Disease: Associations With Gender and Radiation Dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 24-33.	0.4	116
340	Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy. <i>Value in Health</i> , 2008, 11, 172-179.	0.1	70
341	Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. <i>Human Pathology</i> , 2008, 39, 386-392.	1.1	61
342	Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. <i>Archives of Internal Medicine</i> , 2008, 168, 2377.	4.3	304

#	ARTICLE	IF	CITATIONS
343	Caring for the Elderly Cancer Patient: Training the Next Generation of Oncologists. Journal of Oncology Practice, 2008, 4, 193-194.	2.5	2
344	Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 1574.	3.8	89
345	Recommendations on the Use of ¹⁸ F-FDG PET in Oncology. Journal of Nuclear Medicine, 2008, 49, 480-508.	2.8	978
346	Impact of Disease Risk on Efficacy of Matched Related Bone Marrow Transplantation for Pediatric Acute Myeloid Leukemia: The Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 5797-5801.	0.8	100
347	American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges. Journal of Clinical Oncology, 2008, 26, 4022-4026.	0.8	49
348	ASCO Clinical Practice Guidelines: Past, Present and Future. Journal of Oncology Practice, 2008, 4, 236-237.	2.5	4
349	Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008, 111, 4902-4907.	0.6	1,682
350	Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 109-118.	2.3	192
351	Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern. Journal of Oncology Practice, 2008, 4, 114-115.	2.5	8
352	The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 942-953.	2.3	42
353	Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia. , 2008, , 509-530.		1
354	Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. Blood, 2008, 112, 172-172.	0.6	9
355	Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome. Blood, 2008, 112, 2390-2390.	0.6	11
356	Risk Prediction of Chemotherapy-Associated Toxicity in Patients Receiving Cancer Chemotherapy. Translational Medicine Series, 2008, , 1-23.	0.0	0
357	Neutropenia and Its Complications. Translational Medicine Series, 2008, , 1-19.	0.0	0
358	Optimal cancer care across the spectrum of life and disease. American Journal of Managed Care, 2008, 14, 262-4.	0.8	0
359	Variation in the cost of medications for the treatment of colorectal cancer. American Journal of Managed Care, 2008, 14, 717-25.	0.8	29
360	Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. Translational Medicine Series, 2007, , 147-158.	0.0	0

#	ARTICLE	IF	CITATIONS
361	Editorial: Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2007, 3, 187-188.	2.5	1
362	Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 277-284.	0.8	111
363	Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens. <i>Journal of Clinical Oncology</i> , 2007, 25, 2522-2527.	0.8	133
364	ASCO Clinical Practice Guidelines and Beyond. <i>Journal of Oncology Practice</i> , 2007, 3, 330-331.	2.5	4
365	Economics of Cancer Care. <i>Journal of Oncology Practice</i> , 2007, 3, 113-114.	2.5	11
366	Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 217-228.	2.3	21
367	Granulocyte colony-stimulating factors: finding the right indication. <i>Current Opinion in Oncology</i> , 2007, 19, 299-307.	1.1	24
368	Ductal carcinoma in situ: a review of recent advances. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 63-67.	0.9	18
369	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505.	0.8	875
370	Agents under investigation for the treatment and prevention of neutropenia. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1831-1840.	1.9	7
371	Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia. <i>Pharmacoeconomics</i> , 2007, 25, 343-351.	1.7	26
372	Advances in <i>Cancer Investigation</i> . <i>Cancer Investigation</i> , 2007, 25, 515-516.	0.6	0
373	Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2007, 25, 3158-3167.	0.8	639
374	Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2007, 23, 2283-2295.	0.9	150
375	Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. <i>Cancer</i> , 2007, 109, 1011-1018.	2.0	178
376	A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. <i>Cancer</i> , 2007, 110, 1149-1161.	2.0	198
377	Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. <i>Cancer</i> , 2007, 110, 1611-1620.	2.0	119
378	Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. <i>Cancer</i> , 2007, 110, 2339-2346.	2.0	662

#	ARTICLE	IF	CITATIONS
379	The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. <i>Transfusion</i> , 2007, 47, 573-581.	0.8	97
380	Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 632-634.	1.9	1,309
381	A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. <i>Blood</i> , 2007, 110, 372-372.	0.6	2
382	Cost-Effectiveness of Primary Prophylaxis with Pegfilgrastim Versus Filgrastim in Non-Hodgkinâ€™s Lymphoma Patients Receiving CHOP-21.. <i>Blood</i> , 2007, 110, 5166-5166.	0.6	1
383	Myeloid Growth Factors Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 188.	2.3	60
384	Estimating Net Benefits and Harms of Screening Mammography in Women Age 40 to 49 Years. <i>Annals of Internal Medicine</i> , 2007, 147, 882.	2.0	1
385	Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early-Stage Breast Cancer. <i>Translational Medicine Series</i> , 2007, , 137-146.	0.0	0
386	Venous thromboembolism in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1029-1033.	0.6	80
387	Screening mammography at 40â€™49 years: regret or no regret?. <i>Lancet, The</i> , 2006, 368, 2035-2037.	6.3	134
388	Gene Expression Profile Assays as Predictors of Recurrence-Free Survival in Early-Stage Breast Cancer: A Metaanalysis. <i>Clinical Breast Cancer</i> , 2006, 7, 372-379.	1.1	26
389	Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2006, 32, 289-303.	3.4	53
390	2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2006, 24, 3187-3205.	0.8	1,530
391	Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 255-262.	1.1	129
392	Risks and Consequences of Chemotherapy-Induced Neutropenia. <i>Clinical Cornerstone</i> , 2006, 8, S12-S18.	1.0	33
393	Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. <i>Cancer</i> , 2006, 106, 4-16.	2.0	778
394	Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia?. <i>Cancer</i> , 2006, 106, 223-233.	2.0	44
395	Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. <i>Cancer</i> , 2006, 106, 2258-2266.	2.0	983
396	Burden of Pancreatic Cancer and Disease Progression: Economic Analysis in the US. <i>Oncology</i> , 2006, 70, 71-80.	0.9	22

#	ARTICLE	IF	CITATIONS
397	Thromboembolism in Hospitalized Neutropenic Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 484-490.	0.8	424
398	Withholding Antibiotics From Patients With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2006, 24, 1221-1222.	0.8	5
399	Pegfilgrastim Provides Effective Primary Prophylaxis Against Febrile Neutropenia in Patients with NHL Undergoing Chemotherapy: Initial Results from an Integrated Analysis - The Neulasta Versus Current Neutropenia Management Practice (Neucup) Project.. <i>Blood</i> , 2006, 108, 1150-1150.	0.6	1
400	Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.. <i>Blood</i> , 2006, 108, 460-460.	0.6	2
401	Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia. <i>Oncology</i> , 2006, 20, 16-20.	0.4	1
402	Chemotherapy dose intensity and quality cancer care. <i>Oncology</i> , 2006, 20, 16-25.	0.4	42
403	Hemopoiesis and Aging. , 2005, 124, 109-134.		30
404	Time is Money for Both the Healthy and the Sick. <i>Medical Care</i> , 2005, 43, 637-639.	1.1	9
405	Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 557-571.	2.3	88
406	The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. <i>Value in Health</i> , 2005, 8, 149-156.	0.1	61
407	Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy. <i>Value in Health</i> , 2005, 8, 47-52.	0.1	26
408	The strengths and limitations of meta-analyses based on aggregate data. <i>BMC Medical Research Methodology</i> , 2005, 5, 14.	1.4	194
409	Use of re-randomized data in meta-analysis. <i>BMC Medical Research Methodology</i> , 2005, 5, 17.	1.4	15
410	Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. <i>Cancer</i> , 2005, 104, 2822-2829.	2.0	475
411	Length of Stay and Mortality Associated With Febrile Neutropenia Among Children With Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7958-7966.	0.8	123
412	Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy. <i>Archives of Internal Medicine</i> , 2005, 165, 1267.	4.3	238
413	Risk Models for Predicting Chemotherapy-Induced Neutropenia. <i>Oncologist</i> , 2005, 10, 427-437.	1.9	275
414	Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1635-1646.	1.4	38

#	ARTICLE	IF	CITATIONS
415	A Primer in Prognostic and Predictive Models: Development and Validation of Neutropenia Risk Models. Supportive Cancer Therapy, 2005, 2, 168-175.	0.3	6
416	Moving Beyond Febrile Neutropenia. Supportive Cancer Therapy, 2005, 2, 95-97.	0.3	2
417	The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs. Pharmacoeconomics, 2005, 23, 183-192.	1.7	25
418	Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Oncology, 2005, 23, 4198-4214.	0.8	273
419	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7703-7720.	0.8	1,674
420	The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treatment Reviews, 2005, 31, 628-639.	3.4	10
421	Up-Front Therapy for Multiple Myeloma: A Survey of Practice Patterns in the USA.. Blood, 2005, 106, 5172-5172.	0.6	1
422	Myeloid Growth Factors Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 540.	2.3	29
423	A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.. Blood, 2005, 106, 3328-3328.	0.6	0
424	A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. Blood, 2005, 106, 754-754.	0.6	0
425	Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. American Journal of Managed Care, 2005, 11, 313-24.	0.8	174
426	The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opinion on Biological Therapy, 2004, 4, 1897-1910.	1.4	30
427	Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. Journal of Clinical Oncology, 2004, 22, 4302-4311.	0.8	285
428	Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony-Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy. Pharmacotherapy, 2004, 24, 488-494.	1.2	41
429	A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2004, 85, 143-150.	1.1	14
430	Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Supportive Care in Cancer, 2004, 12, 543-9.	1.0	129
431	Chemotherapy-induced neutropenia. Cancer, 2004, 100, 228-237.	2.0	725
432	Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature. Supportive Cancer Therapy, 2004, 2, 34-41.	0.3	16

#	ARTICLE	IF	CITATIONS
433	Prophylactic Pegfilgrastim Significantly Reduces Febrile Neutropenia During Moderately Myelosuppressive Chemotherapy. <i>Supportive Cancer Therapy</i> , 2004, 1, 207-209.	0.3	1
434	Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the united states and other countries. <i>American Journal of Medicine</i> , 2004, 116, 28-34.	0.6	18
435	Economics of Hematopoietic Growth Factors. , 2004, , 409-443.		5
436	First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.. <i>Blood</i> , 2004, 104, 2210-2210.	0.6	14
437	Gene Expression Profile Signatures to Predict Survival in Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Early Results.. <i>Blood</i> , 2004, 104, 2274-2274.	0.6	2
438	Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin's Lymphoma.. <i>Blood</i> , 2004, 104, 4542-4542.	0.6	2
439	Thromboembolism in Hospitalized Neutropenic Cancer Patients.. <i>Blood</i> , 2004, 104, 2199-2199.	0.6	0
440	Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration above 10 g/dL: A Comprehensive Review of Recent Literature.. <i>Blood</i> , 2004, 104, 3714-3714.	0.6	0
441	Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.. <i>Blood</i> , 2004, 104, 4599-4599.	0.6	0
442	Prophylactic Colony-Stimulating Factors in Pediatric Patients Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2004, 104, 2211-2211.	0.6	1
443	Balancing the benefits and costs of colony-stimulating factors: a current perspective. <i>Seminars in Oncology</i> , 2003, 30, 10-17.	0.8	29
444	Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. <i>Cancer</i> , 2003, 98, 2402-2409.	2.0	162
445	The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. <i>BMC Nursing</i> , 2003, 2, 2.	0.9	18
446	Evidence-based oncology in cancer treatment reviews. <i>Cancer Treatment Reviews</i> , 2003, 29, 45-50.	3.4	3
447	Epidemiology of Febrile Neutropenia. <i>Supportive Cancer Therapy</i> , 2003, 1, 23-35.	0.3	92
448	Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. <i>Journal of Clinical Oncology</i> , 2003, 21, 4524-4531.	0.8	416
449	Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy. <i>Leukemia and Lymphoma</i> , 2003, 44, 2069-2076.	0.6	199
450	Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1, 440-454.	2.3	82

#	ARTICLE	IF	CITATIONS
451	Evidence-Based Use of Colony-Stimulating Factors in Elderly Cancer Patients. <i>Cancer Control</i> , 2003, 10, 487-499.	0.7	47
452	Cost effectiveness of myeloid growth factors in cancer chemotherapy. <i>Psychophysiology</i> , 2003, 2, 471-9.	1.1	6
453	Risk assessment in oncology clinical practice. From risk factors to risk models. <i>Oncology</i> , 2003, 17, 8-13.	0.4	16
454	G-CSF as prophylaxis of febrile neutropenia in SCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1273-1281.	0.9	24
455	Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. <i>Current Opinion in Hematology</i> , 2002, 9, 207-214.	1.2	44
456	Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. <i>American Journal of Medicine</i> , 2002, 112, 406-411.	0.6	216
457	Overlooking patient outcomes in a meta-analysis of trials of granulocyte colon-stimulating factor. <i>American Journal of Medicine</i> , 2002, 113, 766-768.	0.6	0
458	Filgrastim in Patients with Neutropenia. <i>Drugs</i> , 2002, 62, 65-78.	4.9	46
459	Exercise Prescription. <i>Annals of Internal Medicine</i> , 2002, 136, 564.	2.0	0
460	Patients Aged ≥ 70 Are at High Risk for Neutropenic Infection and Should Receive Hemopoietic Growth Factors When Treated With Moderately Toxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 1583-1585.	0.8	73
461	Hematopoietic growth factors in the older cancer patient. <i>Current Opinion in Hematology</i> , 2001, 8, 170-187.	1.2	54
462	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. <i>Journal of Clinical Oncology</i> , 2001, 19, 3622-3634.	0.8	2,394
463	Economic analysis of randomized, controlled trials. <i>Current Oncology Reports</i> , 2001, 3, 396-403.	1.8	8
464	Understanding economic analyses. <i>Evidence-based Oncology</i> , 2001, 2, 2-5.	0.1	9
465	Cancer in the Elderly. <i>Annals of Internal Medicine</i> , 2001, 134, 800.	2.0	0
466	Clinical Relevance of Molecular Staging for Melanoma. <i>Annals of Surgery</i> , 2000, 231, 795-803.	2.1	106
467	Evidentiary challenges to evidence-based medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2000, 6, 99-109.	0.9	40
468	Impact of Hot Flashes on Quality of Life Among Postmenopausal Women Being Treated for Breast Cancer. <i>Journal of Pain and Symptom Management</i> , 2000, 19, 436-445.	0.6	107

#	ARTICLE	IF	CITATIONS
469	Understanding treatment benefits and harms. <i>Evidence-based Oncology</i> , 2000, 1, 66-68.	0.1	3
470	A Predictive Model for Neutropenia Associated with Cancer Chemotherapy. <i>Pharmacotherapy</i> , 2000, 20, 104S-111S.	1.2	26
471	Quality of life after adjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 62, 141-150.	1.1	139
472	Hemopoietic Reserve in the Older Cancer Patient: Clinical and Economic Considerations. <i>Cancer Control</i> , 2000, 7, 539-547.	0.7	77
473	What Threshold for Adjuvant Therapy in Older Breast Cancer Patients?. <i>Journal of Clinical Oncology</i> , 2000, 18, 1709-1717.	0.8	203
474	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients with Breast Cancer. <i>Annual Review of Medicine</i> , 2000, 51, 525-542.	5.0	87
475	The uncertainty principle and industry-sponsored research. <i>Lancet</i> , The, 2000, 356, 635-638.	6.3	442
476	Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trialâ€¦; Participants of the second Randomized Intervention Treatment of Angina (RITA-2) trial are listed in the Appendix.. <i>Journal of the American College of Cardiology</i> , 2000, 35, 907-914.	1.2	158
477	Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2000, , CD003039.		19
478	Fatigue in Women Receiving Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Pain and Symptom Management</i> , 1999, 18, 233-242.	0.6	311
479	Update of the economic analyses of the use of the colony-stimulating factors. <i>Current Opinion in Hematology</i> , 1999, 6, 145.	1.2	29
480	Methodological challenges in the evaluation of prognostic factors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998, 52, 289-303.	1.1	239
481	Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. <i>Annals of Surgical Oncology</i> , 1998, 5, 376-383.	0.7	15
482	Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 522-528.	0.7	64
483	Molecular Staging of Malignant Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 1410.	3.8	341
484	Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. <i>Current Opinion in Oncology</i> , 1998, 10, 291-296.	1.1	22
485	Comorbidity and functional status are independent in older cancer patients.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1582-1587.	0.8	930
486	Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1689-1696.	0.8	431

#	ARTICLE	IF	CITATIONS
487	Cancer Care in the Elderly: Cost and Quality-of-Life Considerations. <i>Cancer Control</i> , 1998, 5, 347-354.	0.7	19
488	Guidelines for Sentinel Node Biopsy and Lymphatic Mapping of Patients With Breast Cancer. <i>Annals of Surgery</i> , 1998, 227, 645-653.	2.1	557
489	Sentinel Lymph Node Biopsy in Melanoma of the Head and Neck. <i>Plastic and Reconstructive Surgery</i> , 1997, 100, 591-594.	0.7	147
490	Cancer in the Elderly: Epidemiologic and Clinical Implications. <i>Clinics in Geriatric Medicine</i> , 1997, 13, 1-14.	1.0	44
491	The Role of Selective Lymphadenectomy in Breast Cancer. <i>Cancer Control</i> , 1997, 4, 211-219.	0.7	13
492	Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival. <i>Cancer Control</i> , 1997, 4, 335-341.	0.7	7
493	Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: Clinical outcome. <i>Annals of Surgical Oncology</i> , 1997, 4, 644-649.	0.7	41
494	Bilaterality and recurrence rates for lobular breast cancer: Considerations for treatment. <i>Annals of Surgical Oncology</i> , 1997, 4, 198-202.	0.7	40
495	Importance of race on breast cancer survival. <i>Annals of Surgical Oncology</i> , 1997, 4, 80-87.	0.7	46
496	Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study. <i>Cancer Control</i> , 1996, 3, 1-4.	0.7	22
497	Evaluation of new putative tumor markers for melanoma. <i>Annals of Surgical Oncology</i> , 1996, 3, 558-563.	0.7	55
498	Intraoperative Radiolymphoscintigraphy Improves Sentinel Lymph Node Identification for Patients with Melanoma. <i>Annals of Surgery</i> , 1996, 223, 217-224.	2.1	473
499	Timing of weight gain and breast cancer risk. <i>Cancer</i> , 1995, 76, 243-249.	2.0	60
500	The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. <i>Cancer</i> , 1995, 76, 1634-1642.	2.0	112
501	Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. <i>Clinical Infectious Diseases</i> , 1994, 18, S189-S196.	2.9	7
502	Age as a prognostic factor in the malignant melanoma population. <i>Annals of Surgical Oncology</i> , 1994, 1, 487-494.	0.7	121
503	The effect of changing disease risk on clinical reasoning. <i>Journal of General Internal Medicine</i> , 1994, 9, 488-495.	1.3	37
504	The Orderly Progression of Melanoma Nodal Metastases. <i>Annals of Surgery</i> , 1994, 220, 759-767.	2.1	674

#	ARTICLE	IF	CITATIONS
505	Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. <i>Cancer</i> , 1993, 71, 2764-2768.	2.0	10
506	Overestimation of test effects in clinical judgment. <i>Journal of Cancer Education</i> , 1993, 8, 297-307.	0.6	37
507	A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 1992, 10, 257-263.	0.8	570
508	Advances in current cancer treatment: An overview. <i>Hematological Oncology</i> , 1992, 10, 3-6.	0.8	1
509	Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. <i>Hematological Oncology</i> , 1992, 10, 61-74.	0.8	8
510	RISK FACTORS FOR CANCER. <i>Primary Care - Clinics in Office Practice</i> , 1992, 19, 465-479.	0.7	16
511	Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration. <i>Gynecologic Oncology</i> , 1991, 43, 265-269.	0.6	13
512	Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 1991, 325, 164-170.	13.9	1,342
513	The Effect of Duration of Intervention and Locus of Control on Dietary Change. <i>American Journal of Preventive Medicine</i> , 1991, 7, 341-347.	1.6	13
514	Breast Cancer of the Older Woman: An Annotated Review. <i>Journal of the American Geriatrics Society</i> , 1991, 39, 1113-1123.	1.3	16
515	A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. <i>Cancer</i> , 1991, 67, 245-249.	2.0	20
516	Obesity and body fat distribution and breast cancer prognosis. <i>Cancer</i> , 1991, 67, 523-528.	2.0	67
517	Obesity, body fat distribution, and sex hormones in breast cancer patients. <i>Cancer</i> , 1991, 67, 2215-2218.	2.0	61
518	Estimate of breast cancer risk reduction with weight loss. <i>Cancer</i> , 1991, 67, 2622-2625.	2.0	24
519	Serum cholesterol reduction with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 1990, 17, 3-7.	1.1	32
520	Abdominal Obesity and Breast Cancer Risk. <i>Annals of Internal Medicine</i> , 1990, 112, 182.	2.0	164
521	The value of current nutrition information. <i>Preventive Medicine</i> , 1990, 19, 45-53.	1.6	28
522	Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. <i>In Vitro Cellular & Developmental Biology</i> , 1989, 25, 297-302.	1.0	46

#	ARTICLE	IF	CITATIONS
523	Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. <i>Gynecologic Oncology</i> , 1989, 35, 75-77.	0.6	22
524	Relation of results of exercise stress tests in young women to phases of the menstrual cycle. <i>American Journal of Cardiology</i> , 1988, 61, 197-199.	0.7	42
525	Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. <i>Gynecologic Oncology</i> , 1988, 29, 32-36.	0.6	13
526	Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 1028-1032.	3.3	361
527	LUNG CANCER IN FLORIDA. <i>American Journal of Epidemiology</i> , 1988, 128, 78-84.	1.6	7
528	Cigarette smoking and the, risk of female reproductive cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1987, 157, 35-40.	0.7	80
529	Peritoneal cytology and invasive carcinoma of the cervix. <i>Gynecologic Oncology</i> , 1986, 24, 331-336.	0.6	17
530	Digitalis Use in a Retirement Community. <i>Journal of the American Geriatrics Society</i> , 1986, 34, 504-506.	1.3	4
531	Leukemia and Radium Groundwater Contamination-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1986, 255, 902.	3.8	0
532	Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. <i>Head & Neck</i> , 1986, 9, 104-110.	0.3	82
533	Factors affecting the incidence of infectious morbidity after radical hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 1985, 152, 817-821.	0.7	33
534	High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia A phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 361-364.	0.6	4
535	Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. <i>American Journal of Medicine</i> , 1981, 70, 1222-1229.	0.6	38
536	The Use of Lithium Carbonate to Reduce Infection and Leukopenia during Systemic Chemotherapy. <i>New England Journal of Medicine</i> , 1980, 302, 257-260.	13.9	114
537	The Effect of Lithium Carbonate Administration in Patients with Advanced Small Cell Bronchogenic Carcinoma Receiving Combination Chemotherapy and Radiotherapy. <i>Advances in Experimental Medicine and Biology</i> , 1980, 127, 207-229.	0.8	4
538	Fibrinogen kinetics in patients with neoplastic disease. <i>Cancer</i> , 1978, 41, 1113-1122.	2.0	47
539	Combination Chemotherapy and Radiation Therapy of Undifferentiated Small Cell Bronchogenic Carcinoma. <i>Southern Medical Journal</i> , 1978, 71, 519-524.	0.3	11
540	Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy. <i>American Journal of Hematology</i> , 1977, 3, 209-218.	2.0	62

#	ARTICLE	IF	CITATIONS
541	Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of friend leukemic cell differentiation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1976, 448, 460-473.	1.4	66
542	Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation. <i>Nature</i> , 1976, 262, 360-363.	13.7	221
543	The myeloid growth factors in older adults with cancer. , 0, , 323-337.		0
544	Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation. <i>Cancer Investigation</i> , 0, , 1-9.	0.6	0